Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients

Transplantation

Volumn 87, Issue 8, 2009, Pages 1221-1224

  Amundsen, Rune ^a   Åsberg, Anders ^a   Robertsen, Ida ^a   Vethe, Nils T ^b   Bergan, Stein ^b   Hartmann, Anders ^b   Midtvedt, Karsten ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cyclosporine A; Pharmacokinetics; Renal transplantation; Rimonabant; Tacrolimus

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID; PREDNISOLONE; RIMONABANT; TACROLIMUS; ANTIOBESITY AGENT; CANNABINOID; CYCLOSPORIN; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG WITHDRAWAL; FEMALE; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; MENTAL DISEASE; MORNING DOSAGE; NIGHTMARE; OBESITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; SIDE EFFECT; SLEEP DISORDER; BLOOD; CADAVER; DONOR; DRUG INTERACTION; IMMUNOLOGY; KINETICS; LIVING DONOR; MIDDLE AGED;

ADULT; ANTI-OBESITY AGENTS; AREA UNDER CURVE; CADAVER; CANNABINOIDS; CYCLOSPORINE; DRUG INTERACTIONS; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; KINETICS; LIVING DONORS; MALE; MIDDLE AGED; PIPERIDINES; PYRAZOLES; TACROLIMUS; TISSUE DONORS;

EID: 65549165930     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31819f1001     Document Type: Article

References (37)

1. Kasiske BL, Guijarro C, Massy ZA, et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158.
2. Aakhus S, Dahl K, Wideroe T. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 1999; 14: 648.
3. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112.
4. Hausberg M, Kisters K, Kosch M, et al. Flow-mediated vasodilation and distensibility of the brachial artery in renal allograft recipients. Kidney Int 1999; 55: 1104.
5. Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age 1. Transplantation 1997; 64: 979.
6. Hjelmesaeth J, Hartmann A, Leivestad T, et al. The impact of earlydiagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006; 69: 588.
7. Hjelmesaeth J, Midtvedt K, Jenssen T, et al. Insulin resistance after renal transplantation: Impact of immunosuppressive and antihypertensive therapy. Diabetes Care 2001; 24: 2121.
8. Holdaas H, Fellström B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024.
9. Midtvedt K, Hartmann A, Foss A, et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril1. Transplantation 2001; 72: 1787.
10. Åsberg A, Berg KJ, Hartmann A. Each administration of cyclosporin A enhances skin microvascular reactivity in renal transplant recipients. Microvasc Res 2000; 60: 81.
11. James WPT. The epidemiology of obesity: The size of the problem. J Intern Med 2008; 263: 336.
12. Jezior D, Krajewska M, Madziarska K, et al. Posttransplant overweight and obesity: Myth or reality? Transplant Proc 2007; 39: 2772.
13. Jezior D, Krajewska M, Madziarska K, et al. Weight reduction in renal transplant recipients program: The first successes. Transplant Proc 2007; 39: 2769.
14. Jindal RM, Zawada ET. Obesity and kidney transplantation. Am J Kidney Dis 2004; 43: 943.
15. Bouchard JF, Le'picier P, Lamontagne D. Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci 2003; 72: 1859.
16. Ja'rai Z, Wagner JA, Varga K, et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 1999; 96: 14136.
17. Randall MD, Alexander SPH, Bennett T, et al. An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem Biophys Res Commun 1996; 229: 114.
18. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study. Lancet 2006; 368: 1660.
19. HoWSV, Hiley CR. Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. Br J Pharmacol 2003; 138: 1320.
20. Patel PN, Pathak R. Rimonabant: A novel selective cannabinoid-1 receptor antagonist for treatment of obesity. Am J Health Syst Pharm 2007; 64: 481.
21. Christians U, Sewing KF. Cyclosporin metabolism in transplant patients. Pharmacol Ther 1993; 57: 291.
22. Sattler M, Guengerich FP, Yun CH, et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992; 20: 753.
23. Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077.
24. Colleran K, Pai H. Rimonabant: A novel approach for the treatment of obesity and cardiometabolic risk by blockade of the endocannabinoid system. Future Cardiol 2007; 3: 497.
25. Grandison MK, Kanamaluru V, Lockwood G, et al. Lack of effect of rimonabant on the pharmacokinetics of midazolam. J Clin Pharmacol 2005; 45: 1082.
26. Kanamaluru V, Lockwood G, Bonnet D, et al. Lack of effect of rimonabant on the pharmacokinetics of digoxin. J Clin Pharmacol 2005; 45: 1081.
27. World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2000; 284: 3043.
28. Falck P, Guldseth H, Asberg A, et al. Determination of ciclosporin A and its six main metabolites in isolated T-lymphocytes and whole blood using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 852: 345.
29. Taylor PJ, Brown SR, Cooper DP, et al. A high-throughput LC/MS/MS method for tacrolimus measurement in kidney and liver transplant patients. Waters 2007; APNT10053586.
30. Nankivell BJ, Gruenewald SM, Allen RD, et al. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683.
31. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a WHO/IDF consultation. Geneva, World Health Organization 2006.
32. European Medicines Agency (EMEA). Note for guidance on the investigation of bioavailability and bioequivalence. London, EMEA 2001.
33. Lemahieu WPD, Hermann M, Asberg A, et al. Combined therapy with atorvastatin and calcineurin inhibitors: No interactions with tacrolimus. Am J Transplant 2005; 5: 2236.
34. Despres JP, Golay A, Sjostrom L, et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121.
35. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. JAMA 2006; 295: 761.
36. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIOEurope study. Lancet 2005; 365: 1389.
37. Janiak P, Poirier B, Bidouard JP, et al. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese zucker rats. Kidney Int 2007; 72: 1345.